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Recommendations for Laboratory Testing for Acetyl Fentanyl and 
Patient Evaluation and Treatment for Overdose with Synthetic Opioids
Summary: Recently, a number o f intravenous drug users have overdosed on a new, non-prescription 
injected synthetic opioid, acetyl fentanyl. Acetyl fentanyl is a fentanyl analog previously undocumented in 
illicit drug use that is up to five times more potent than heroin. CDC recommends increased vigilance by 
public health agencies, emergency departments, state laboratories, medical examiners, and coroners for 
patients with symptoms consistent with opioid overdose and laboratory results showing an enzyme-linked 
immunosorbent assay (ELISA) positive for fentanyl.
CDC also recommends that public health officials work with laboratories to carry out ELISA screens for 
fentanyl, and i f  the results o f these screens are positive for fentanyl, conduct gas chromatography-mass 
spectrometry (GC/MS) confirmatory testing on specimens to confirm or rule out fentanyl and its analogs, 
including acetyl fentanyl.
Background:
Since March 6, 2013, 14 overdose deaths related to a novel, injected non-prescription synthetic opioid 
have occurred among intravenous drug users in Rhode Island. Ten of those deaths occurred in March. 
On May 30, 2013, Rhode Island Department of Health confirmed that the implicated synthetic opioid is 
acetyl fentanyl, a fentanyl analog previously undocumented in illicit drug use. Acetyl fentanyl is not 
available as a prescription drug in the U.S.
The age of the persons who died from an acetyl fentanyl overdose ranged from 19 -  57 years, and 10 of 
the decedents were male. The toxicology testing results for most of the decedents showed, in addition to 
acetyl fentanyl, varying mixtures of drugs, including cocaine, heroin (morphine), ethanol, and 
benzodiazepines. However, none of these additional substances were present in all decedents and none 
of these persons tested positive for fentanyl by GC/MS after testing positive for fentanyl by ELISA. 
Toxicology results for one decedent showed only acetyl fentanyl (by GC/MS) and no other substances. 
These deaths represent a significant increase in the number of illicit drug overdose deaths compared with 
the number of cases typically reported in one month in Rhode Island.
There have been unconfirmed reports from other states of increases in illicit opioid-related overdose 
events seen in emergency departments. Media stories have associated these events with “fentanyl- 
contaminated heroin” or, in some cases, to fentanyl alone. It is possible that these events are related to 
acetyl fentanyl, but confirmatory testing is needed. States other than Rhode Island have not informed 
CDC that they are testing for acetyl fentanyl.
Case definitions:
1. Illicit opioid-related overdose: A diagnosis by a physician of illicit opioid overdose.
Note: If a suspected illicit opioid overdose event results in death, jurisdictions often carry out drug 
screening. Some jurisdictions perform an ELISA that includes a screen for fentanyl, while others 
do not routinely screen for fentanyl. CDC recommends screening for fentanyl by ELISA to
improve the detection of fentanyl-related overdose deaths.
2. Suspected fentanyl overdose death: An overdose death in a person who tests positive for 
fentanyl by ELISA screen.
Note: Some jurisdictions routinely screen for fentanyl, but do not perform confirmatory GC/MS 
testing. If the ELISA screen is positive for fentanyl and GC/MS confirmatory testing does not take 
place, an overdose death may be incorrectly attributed to fentanyl. CDC strongly encourages 
confirmatory GC/MS testing to determine if suspected fentanyl overdose deaths are caused by 
fentanyl, acetyl fentanyl, or another fentanyl analog (see case definition 3 below).
3. Acetyl fentanyl overdose death: An acetyl fentanyl overdose death in a person who initially tests 
positive for fentanyl by ELISA assay, but upon confirmatory GC/MS testing, tests positive for 
acetyl fentanyl rather than fentanyl. In these cases, the GC/MS results show a distinct 
chromatographic peak with a mass spectrum consistent with acetyl fentanyl or 4-Anilino-n- 
phenethylpiperdine (ANPP -  a compound believed to be a precursor of acetyl fentanyl).
Recommendations:
Health care and clinical recommendations:
Because of these reports of increases in illicit opioid-related overdose events, CDC encourages 
emergency departments and emergency response services to exercise increased vigilance in 
promptly identifying suspected opioid overdose patients and taking appropriate action. Because 
acetyl fentanyl is a synthetic opioid, it is believed that naloxone will have the same reversal effect as it 
does for fentanyl and other synthetic opioids. We recommend that emergency departments and 
emergency medical services treat suspected opioid overdoses according to standard protocols. In 
addition, larger doses of naloxone may be required to reverse the opioid induced respiratory depression 
because of the higher potency of fentanyl and acetyl fentanyl compared to heroin. CDC advises that 
emergency departments and emergency medical services ensure that they have adequate naloxone 
available, as some agencies have run out of naloxone in the face of increased numbers of overdoses and 
administering higher doses of naloxone in a short period of time.
Laboratory testing recommendations and additional information:
Since acetyl fentanyl might be the substance of interest in cases in which the result of the ELISA screen 
is positive for fentanyl but GC/MS is not conducted, toxicology laboratories should conduct both 
ELISA screens and GC/MS confirmatory testing on samples from illicit opioid-related overdose 















Recovered by routine n-butyl chloride liquid: liquid basic drug extraction, 
including an acid back extraction. Sensitivity of method not yet 
established.
GC/MS EI Scan
Ions 231, 146, 188 m/z and earlier eluter metabolite/breakdown ANPP 
146, 189 m/z
Citalopram, ANPP , Paroxetine, ACETYL FENTANYL, Fentanyl, 
Zolpidem
See chromatographic peak, mass spectrum, and chemical structure of acetyl fentanyl in the exhibit below. 
Exhibit:
For more information:
Public health agencies, state laboratories, medical examiners, coroners, and emergency departments 
should contact CDC if they have seen any of the following:
• An increase in illicit opioid-related overdose events (morbidity and/or mortality) from January 1, 
2013 to present, with or without evidence of fentanyl (see case definitions 1 and 2).
• Any individual or clusters of illicit opioid-related overdose events with evidence of acetyl fentanyl 
or other fentanyl analog confirmed by GC/MS (see case definition 3).
Please contact one of the following CDC epidemiologists for more information:
Matthew Lozier, PhD, MPH 
Email: mlozier@cdc.gov 
Phone: (770) 488-0794
Colleen Martin, MSPH 
Email: CMartin5@cdc.qov 
Phone: (770) 488-1468
The Centers fo r  Disease Control and Prevention (CDC) protects people's health and safety by preventing and 
controlling diseases and injuries; enhances health decisions by providing credible information on critical health 
issues; and promotes healthy living through strong partnerships with local, national, and international
organizations.
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